NeuroVive Pharmaceutical AB Ár/értékesítés
Mi az NeuroVive Pharmaceutical AB Ár/értékesítés?
A Ár/értékesítés az NeuroVive Pharmaceutical AB - 1,207.19
Mi a Ár/értékesítés meghatározása?
Az ár / árbevétel arány a vállalat részvényeinek árbevételéhez képest.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Ár/értékesítés a Miscellaneous szektor a LSE-on cégekben a NeuroVive Pharmaceutical AB -hoz képest
Mit csinál NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
ár/értékesítés -hoz hasonló cégek NeuroVive Pharmaceutical AB
- CytoDyn nak Ár/értékesítés 1,174.39 van
- Cellular Biomedicine Inc nak Ár/értékesítés 1,184.26 van
- Black Rock Mining nak Ár/értékesítés 1,188.66 van
- Navidea Biopharmaceuticals Inc nak Ár/értékesítés 1,194.84 van
- Kraig Biocraft Laboratories nak Ár/értékesítés 1,199.03 van
- Buderim nak Ár/értékesítés 1,206.67 van
- NeuroVive Pharmaceutical AB nak Ár/értékesítés 1,207.19 van
- Strategic Elements Ltd nak Ár/értékesítés 1,216.32 van
- Greenland Minerals nak Ár/értékesítés 1,251.46 van
- Galantas Gold nak Ár/értékesítés 1,271.42 van
- Kazia Therapeutics nak Ár/értékesítés 1,276.66 van
- Tyranna Resources nak Ár/értékesítés 1,282.36 van
- Leading Leasing Finance And Investment nak Ár/értékesítés 1,283.53 van